GlassScriptPhysician profile
Christopher J Welty
NPI 1750571360
$10,305.18
in general payments reported to CMS, 2019-2025
67 companies · $2,516 in 2025
The $2,516 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $362 · 2021: $791 · 2022: $2,350 · 2023: $1,617 · 2024: $1,795 · 2025: $2,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498 · Travel and Lodging: $413 · Education: $16.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,498.45 |
| Travel and Lodging | $412.96 |
| Education | $16.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $882.80 | 2019-2024 | |
| Astellas Pharma US INC | $749.26 | 2019-2025 | Myrbetriq, Padcev, Veozah |
| Urogen Pharma, INC. | $674.15 | 2021-2025 | Jelmyto |
| Sumitomo Pharma America, INC. | $619.21 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $618.03 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Antares Pharma, INC. | $529.47 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Ferring Pharmaceuticals INC. | $517.18 | 2019-2025 | Adstiladrin, Menopur |
| Abbvie INC. | $515.29 | 2019-2025 | Botox, Lupron Depot |
| Angiodynamics, INC. | $443.55 | 2019-2025 | Nanoknife |
| Myriad Genetic Laboratories, INC. | $331.18 | 2021-2025 | Prolaris, Myrisk |
| Merck Sharp & Dohme LLC | $287.32 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $276.77 | 2019-2025 | |
| Axonics, INC. | $268.54 | 2022-2024 | Bulkamid, Axonics |
| Dendreon Pharmaceuticals LLC | $224.49 | 2019-2025 | Provenge |
| Myovant Sciences INC. | $212.99 | 2021-2022 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Welty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.